Tax Inversion Action? Clock Ticks on Pfizer-Allergan Merger – ValueWalk Premium
Tax Inversion Pfizer-Allergan Merger

Tax Inversion Action? Clock Ticks on Pfizer-Allergan Merger

As the Pfizer-Allergan merger talks heat up, shining yet another spotlight on the tax inversion issue, a Goldman Sachs report notes that it is up to the U.S. Treasury and IRS to stem flood of corporations fleeing the U.S. tax system for more friendly climates abroad.


Pfizer / Allergan acquisition would result in a tax inversion, as clock is ticking
If drug giant Pfizer Inc. is successful in . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email support@valuewalk.com or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk
Here’s a Tip: Read What Professional Investors Read

ValueWalk Premium is for investors looking to improve their investment process AND keep up-to-date on the latest industry trends.

It’s THE resource for value investing and hedge funds.   

And with a free three-day trial and $29.99 per month thereafter, it’s a value in its own right.

SIGN UP NOW
0